TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 389351

Group type: EXPERIMENTAL
Intervention: Amoxycillin 3 g
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Ampicillin 3 g plus probenecid 1 g
Number of subjects: 160
Study: 30922317

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate (ASAQ)
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: mefloquine-artesunate (MQAS)
Number of subjects: 3127

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 3127
Study: 29289942

Group type: EXPERIMENTAL
Intervention: High quality care (38% of patients)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Moderate quality care (11% of patients)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: Low quality care (17% of patients)
Number of subjects: 1724

Group type: EXPERIMENTAL
Intervention: No quality care (35% of patients)
Number of subjects: 1724
Study: 24532801

Group type: EXPERIMENTAL
Intervention: Social-skills training and parental training plus standard treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 47
Study: 23494184

Group type: EXPERIMENTAL
Intervention: SERI
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scarf
Number of subjects: 20
Study: 20930708

Group type: EXPERIMENTAL
Intervention: Evening ingestion of ACE inhibitors (benazepril, captopril, enalapril, lisinopril, perindopril, quinapril, ramipril, spirapril, trandolapril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evening ingestion of ARBs (irbesartan, olmesartan, telmisartan, valsartan)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotherapy (timing of treatment to body rhythms)
Number of subjects: 0
Study: 19344560

Group type: EXPERIMENTAL
Intervention: Cefalotin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 16948837

Group type: EXPERIMENTAL
Intervention: Bagged larvae
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Loose larvae
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard treatment (hydrogel)
Number of subjects: 35
Study: 15107659

Group type: EXPERIMENTAL
Intervention: Granisetron (n=5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 12
Study: 11682388

Group type: EXPERIMENTAL
Intervention: BIS-Titrated group (n = 32)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 9167508

Group type: EXPERIMENTAL
Intervention: Subanesthetic doses of ketamine
Number of subjects: 17
Study: 7948468

Group type: EXPERIMENTAL
Intervention: Glucose ingestion (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water ingestion
Number of subjects: 0
Study: 2893080

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg thrice a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Frusemide 40 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28279123

Group type: EXPERIMENTAL
Intervention: Oral clarithromycin (7.5 mg/kg, twice a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 40
Study: 28538060

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 26958294

Group type: EXPERIMENTAL
Intervention: Image-based dietitian support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile-based visual diary
Number of subjects: 0
Study: 24334921

Group type: EXPERIMENTAL
Intervention: Type I diet (low in carbohydrates)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Type II diet (low in fats)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 280
Study: 21142464

Group type: EXPERIMENTAL
Intervention: Lumbar spinous process-splitting laminectomy (LSPSL)
Number of subjects: 41
Study: 18942898

Group type: EXPERIMENTAL
Intervention: 80 mg bolus of pantoprazole followed by continuous infusion of 8 mg/h for 72 hours (group 0)
Number of subjects: 41

Group type: COMPARATOR
Intervention: 40 mg of pantoprazole administered intravenously daily (group 1)
Number of subjects: 41
Study: 17275361

Group type: EXPERIMENTAL
Intervention: Compression plus superficial venous surgery
Number of subjects: 500

Group type: COMPARATOR
Intervention: Multilayer compression
Number of subjects: 500
Study: 15356822

Group type: EXPERIMENTAL
Intervention: Rifampin and Pyrazinamide (RZ)
Number of subjects: 1466

Group type: COMPARATOR
Intervention: Isoniazid (INH)
Number of subjects: 1466
Study: 11297719

Group type: EXPERIMENTAL
Intervention: Active rTMS for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 18
Study: 9386661

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) technique with a PEP mask (Astra Meditec)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional postural drainage and percussion (PD&P)
Number of subjects: 40
Study: 8131199

Group type: EXPERIMENTAL
Intervention: Soap enema
Number of subjects: 200

Group type: COMPARATOR
Intervention: No enema (control)
Number of subjects: 200
Study: 2445316

Group type: EXPERIMENTAL
Intervention: Flecainide (200 to 400 mg per day)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Amiodarone (800 to 400 mg per day)
Number of subjects: 81
Study: 29136550

Group type: EXPERIMENTAL
Intervention: Active cerebellar transcranial direct current stimulation (ctDCS), 1 mA, 20 min (N=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham cerebellar transcranial direct current stimulation (sham-ctDCS) (N=14)
Number of subjects: 28
Study: 27546353

Group type: EXPERIMENTAL
Intervention: Real time myocardial perfusion echocardiography (RT‐MPE)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Infarct mass
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Myocardial blood flow (MBF)
Number of subjects: 27
Study: 24780069

Group type: EXPERIMENTAL
Intervention: ZNF259 rs2075290, ZNF259 rs964184 and BUD13 rs10790162 SNPs
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: BUD13 rs10790162
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: G-G-A-A-C-C haplotype (carrying rs964184-G-allele)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: A-C-G-G-C-C haplotype (carrying rs964184-C-allele)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: A-C-A-G-T-C haplotype (carrying rs964184-C-allele)
Number of subjects: 1181

Group type: EXPERIMENTAL
Intervention: Two- to three-locus models
Number of subjects: 1181
Study: 22375972

Group type: EXPERIMENTAL
Intervention: Nicotine patches (15 mg per 16 hours)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study: 20889941

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.3%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine 0.2%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 18519872

Group type: EXPERIMENTAL
Intervention: istradefylline 20 mg/day
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: istradefylline 60 mg/day
Number of subjects: 395

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 395
Study: 15837452

Group type: EXPERIMENTAL
Intervention: One-item measure of mental health status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Five-item measure of mental health status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reliable instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any valid instrument
Number of subjects: 0
Study: 12004017

Group type: EXPERIMENTAL
Intervention: Cefuroxime-impregnated cement (Group 1, 178 knees)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Cement without cefuroxime (Group 2, 162 knees)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cefuroxime-impregnated cement (Group 1)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Cement without cefuroxime (Group 2)
Number of subjects: 340
Study: 10090188

Group type: EXPERIMENTAL
Intervention: Methotrexate combined with cyclosporine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate and placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisone plus methotrexate plus sulfasalazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfasalazine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AUC summary
Number of subjects: 0

Group type: COMPARATOR
Intervention: EOS
Number of subjects: 0
Study: 7559252

Group type: EXPERIMENTAL
Intervention: External flow resistive mechanical loads (R1/E1, R2/E2)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Elastic mechanical loads (R1/E1, R2/E2)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Imperceptible loads (R0/E0)
Number of subjects: 5
Study: 2140748

Group type: EXPERIMENTAL
Intervention: Polyvalent oral bacterial vaccine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 343312

Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 - 2.0 g per day for 6 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Metronidazole (1.0 - 2.0 g per day for 6 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 g per day for 7 days)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Panidazole (1.0 g per day for 10 days)
Number of subjects: 118
Study: 31968697

Group type: EXPERIMENTAL
Intervention: Dietary advice including green vegetables five times per week, beef three times per week, 300 mL whole milk per day, and whole dairy butter on bread every day plus standard supportive care.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Standard supportive care alone.
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dietary advice group.
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 118
Study: 30442033

Group type: EXPERIMENTAL
Intervention: Community-based navigator intervention
Number of subjects: 179
Study: 28432606

Group type: EXPERIMENTAL
Intervention: Electrostimulation group (ESG) underwent RCAVF NMES programme
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (CG) underwent usual RCAVF forearm exercises
Number of subjects: 36
Study: 25774625

Group type: EXPERIMENTAL
Intervention: Low-intensity fast velocity (LIFV) squat protocol (5 × 16 at 40% 1 repetition maximum)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traditional high-intensity slow velocity (TISV) squat protocol (5 × 8 at 80% 1RM)
Number of subjects: 17
Study: 22402673

Group type: EXPERIMENTAL
Intervention: Oral 150 mg monthly ibandronate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study: 20605242

Group type: EXPERIMENTAL
Intervention: Paclitaxel eluting stent (Infinium, Sahajanand Medical Technologies Pvt Ltd.)
Number of subjects: 13
Study: 19186964

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap (MCAF) with platelet-rich fibrin (PRF) membrane
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified coronally advanced flap (MCAF) alone (control)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Modified coronally advanced flap (MCAF) with PRF
Number of subjects: 20
Study: 17708612

Group type: EXPERIMENTAL
Intervention: Fuzheng Yiliu granules (body‐resistance strengthening and tumor‐suppressing granules) with radiotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 63
Study: 15570645

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pamidronate 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BASMI (0-2 scoring)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BASMI (0-10 scoring)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Individual components of BASMI (cervical rotation, lumbar side flexion)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: BASMI
Number of subjects: 70
Study: 11480815

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine (CHX) solution
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine (CHX) with fluoride
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 0.06% chlorhexidine (CHX) without fluoride
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (ASF) solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 81
Study: 9726723

Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg
Number of subjects: 12
Study: 8035399

Group type: EXPERIMENTAL
Intervention: Education only group received a 6-week self-management course.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Education plus physical training group received the course and 6 hours of training.
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group received treatment after 3 months.
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Physical training group (part of education plus physical training).
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: All subjects post-intervention.
Number of subjects: 99
Study: 2538577

Group type: EXPERIMENTAL
Intervention: CEV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, etoposide 50 mg/m2 IV day 1, followed by etoposide 100 mg/m2/day orally days 2 through 5)
Number of subjects: 353

Group type: COMPARATOR
Intervention: CAV regimen (cyclophosphamide 1,000 mg/m2 IV day 1, vincristine 1.4 mg/m2 IV day 1, doxorubicin 50 mg/m2 IV day 1)
Number of subjects: 353

Group type: COMPARATOR
Intervention: CV regimen (cyclophosphamide 2,000 mg/m2 day 1, vincristine 1.4 mg/m2 IV day 1)
Number of subjects: 353
Study: 983073

Group type: EXPERIMENTAL
Intervention: 50 mg pentazocine plus 500 mg acetylsalicylic acid (P + A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thermal method (fixed intensity-variable time modification)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Visual stimuli reaction time measurement
Number of subjects: 10
Study: 31157568

Group type: EXPERIMENTAL
Intervention: PREDICT-DM model
Number of subjects: 30000000
Study: 26576503

Group type: EXPERIMENTAL
Intervention: 40% VO2peak
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 60% VO2peak
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Post-exercise at 40-60% VO2peak
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ≥80% VO2peak
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 60% to 90% VO2peak
Number of subjects: 17
Study: 25916930

Group type: EXPERIMENTAL
Intervention: B-ultrasound monitoring plus gastric insufflation (C)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Gastric insufflation (B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Routine (A)
Number of subjects: 96
Study: 23389626

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy
Number of subjects: 118
Study: 20848671

Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT and conventional ES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT and dynamic ES
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMG biofeedback‐assisted PFMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 19404176

Group type: EXPERIMENTAL
Intervention: Modified techniques applied to 19 patients (investigational group)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard techniques applied to 20 patients (control group)
Number of subjects: 39
Study: 17853049

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 10
Study: 14759393

Group type: EXPERIMENTAL
Intervention: rosiglitazone (4 mg/day)
Number of subjects: 50
Study: 11724948

Group type: EXPERIMENTAL
Intervention: Chlorophyllin (100 mg, three times a day for 4 months)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 9228872

Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10
Study: 7957525

Group type: EXPERIMENTAL
Intervention: 100 IU synthetic salmon calcitonin (i.v.)
Number of subjects: 15
Study: 3666261

Group type: EXPERIMENTAL
Intervention: Meptazinol 100 mg
Number of subjects: 199

Group type: COMPARATOR
Intervention: Pethidine 75 mg
Number of subjects: 199
Study: 29069359

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 14511

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 14511

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14511
Study: 27383377

Group type: EXPERIMENTAL
Intervention: 300 mg spironolactone (MR antagonist)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 71
Study: 26310855

Group type: EXPERIMENTAL
Intervention: Topical anesthetic (EMLA® or Numby®) plus subcutaneous buffered lidocaine (SQBL)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Topical anesthetic (EMLA® or Numby®) only
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Topical anesthetic (EMLA® or Numby®) plus SQBL
Number of subjects: 63
Study: 23526241

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and Aspirin 150 mg capsule (test formulation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lipitor® tablets 10 mg and Nu‐Seals tablets 75 mg (reference formulations)
Number of subjects: 80
Study: 19760530

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication and sexual arousal experimental manipulation using erotic film clips
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive role‐play videos tailored for measuring risk perception and communication skills
Number of subjects: 0
Study: 17709266

Group type: EXPERIMENTAL
Intervention: i.v. AG supplementation (0.3 g/kg day from day 4 till 17) and i.v. GH (0.05 mg/kg day divided into 8 boluses, maximum dose at 3 AM, administered on days 7‐17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: AG and placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isocaloric isonitrogenous nutrition without AG
Number of subjects: 30
Study: 15917338

Group type: EXPERIMENTAL
Intervention: CsA-MMF group
Number of subjects: 151

Group type: COMPARATOR
Intervention: MMF group
Number of subjects: 151
Study: 12891293

Group type: EXPERIMENTAL
Intervention: Ticlopidine (1000 mg/day for 2 days and then 500 mg/day for 5 days, n=19)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg/day for 1 day and then 75 mg/day for 6 days, n=10)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No ticlopidine (n=18)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No clopidogrel (n=9)
Number of subjects: 56
Study: 15312862

Group type: EXPERIMENTAL
Intervention: CABG during index hospitalization
Number of subjects: 2220

Group type: COMPARATOR
Intervention: Prior CABG history
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Elevated troponin
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Prior stable angina
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: ST-segment deviation >or=0.5 mm
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: History of peripheral arterial disease
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Risk score <3.0
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Risk score 3 to 5
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Risk score >5.0
Number of subjects: 2220

Group type: EXPERIMENTAL
Intervention: Risk score association with CABG
Number of subjects: 2220
Study: 10440606

Group type: EXPERIMENTAL
Intervention: Omeprazole (10-20 mg for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (for 4 weeks)
Number of subjects: 24
Study: 7849885

Group type: EXPERIMENTAL
Intervention: MDI with spacer
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nebulizer
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 152
Study: 2121202

Group type: EXPERIMENTAL
Intervention: CW 200 ventilator
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nuffield 200 ventilator
Number of subjects: 20
Study: 360758

Group type: EXPERIMENTAL
Intervention: XYY men
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: XXY men
Number of subjects: 78

Group type: COMPARATOR
Intervention: XY men
Number of subjects: 78
Study: 30880374

Group type: EXPERIMENTAL
Intervention: 20 needle biopsy with decision analysis approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longer needles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing the number of biopsy cores from 10-12 to about 20
Number of subjects: 0
Study: 28799216

Group type: EXPERIMENTAL
Intervention: Structured physical activity intervention
Number of subjects: 1590

Group type: COMPARATOR
Intervention: Health education (HE) program
Number of subjects: 1590
Study: 26205444

Group type: EXPERIMENTAL
Intervention: Absorb scaffold
Number of subjects: 501

Group type: COMPARATOR
Intervention: EES
Number of subjects: 501
Study: 23657065

Group type: EXPERIMENTAL
Intervention: QD of 400 mL/min with QB of 200 mL/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: QD of 400 mL/min with QB of 210 mL/min (condition B')
Number of subjects: 12

Group type: COMPARATOR
Intervention: QD of 500 mL/min with QB of 200 mL/min (condition A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: QD of 500 mL/min with QB of 150 mL/min (condition B)
Number of subjects: 12
Study: 20959524

Group type: EXPERIMENTAL
Intervention: Single doses of dexpramipexole (50 mg, 150 mg, or 300 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Multiple doses of dexpramipexole (50 mg twice daily, 100 mg twice daily, or 150 mg twice daily) over 4.5 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Single doses of dexpramipexole
Number of subjects: 54
Study: 19840648

Group type: EXPERIMENTAL
Intervention: Excite DSC (n = 20)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: AH‐26 (n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no sealer, n = 2)
Number of subjects: 42
Study: 16889080

Group type: EXPERIMENTAL
Intervention: Tamsulone-FS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omnik
Number of subjects: 0